Here we go again with the “two-decade-old tech” line—like it hasn’t been debunked a dozen times.
Yes, the original concept for RadioGel™ was developed years ago—like most breakthrough medical tech. So were mRNA platforms, immunotherapies, and dozens of other innovations that evolved over time. What matters now is the current formulation, the new patents, and the clinical readiness of the product being submitted to the FDA.
The current version of RadioGel has:
New polymer formulations (like PLGA-g-PEG),
Updated manufacturing protocols,
New U.S. and international patents granted and pending,
And an IDE submission that’s based on modern safety and compatibility data—not something from 2005.
To claim the tech is “generic public domain” is just disingenuous. The original patents may have expired—but that’s not what’s being trialed today. The device going into humans now is backed by proprietary science and protected IP. That’s why it's still a regulated medical device and not something anyone can just throw together in a lab.
Let’s stop pretending that old ideas can’t evolve into powerful new treatments. If that logic held up, there would be no innovation in cancer therapy at all.
But maybe that’s the point here—discredit progress, twist facts, and hope people aren’t paying attention. Doesn’t work here.
$RDGL
Market Data 
Markets 
AI
